BRIEF—Calliditas Therapeutics appoints new regulatory affairs chief

Calliditas Therapeutics has appointed Frank Bringstrup as VP of regulatory affairs, leading regulatory efforts related to the firm’s Phase III NEFIGARD study of people with IgA nephropathy (IgAN).

Dr Bringstrup has worked in various positions at Novo Nordisk, most recently as senior global regulatory lead.

Chief executive Renée Aguiar-Lucander said: “The combination of his strong experience in regulatory affairs, not only with the FDA but on a broad international basis with a proven track record and experience from orphan drug development and bringing products to market will play a key role as we progress development of Nefecon through Phase III clinical trials.”